Positive News for Two Undervalued Firms in the Prohost Portfolio

Exelixis CABOMETYX Approval
Exelixis (EXEL) partner Ipsen received approval from the European Commission (EC) for CABOMETYX® (cabozantinib) as a monotherapy for the treatment of adult patients with locally advanced or metastatic differentiated thyroid carcinoma (DTC), which is refractory or not eligible to radioactive iodine (RAI . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.